ArticleAntibiotics (Basel, Switzerland)2024
Molecular Analysis of Carbapenem and Aminoglycoside Resistance Genes in Carbapenem-Resistant
Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- In Silico Mutational Analysis of Two-Component System Genes Associated with Colistin Resistance in ClinicalBiomolecules · 2026Article
- Comparative genome analysis of carbapenemase-producing Pseudomonas aeruginosa: gene diversity, clonal distribution, and genome dynamics.Molecular genetics and genomics : MGG · 2026Article
- Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates obtained from patients treated in a paediatric hospital in Mexico.Scientific reports · 2026Article
- Functional characterization of a novel class A carbapenemase CAE-1 in carbapenem-resistantAntimicrobial agents and chemotherapy · 2026Article
- Landscape of resistance to ceftolozane/tazobactam and ceftazidime/avibactam in strains of Pseudomonas aeruginosa: a genomic approach in strains without selection pressure in a tertiary-care paediatric hospital in Mexico.BMC infectious diseases · 2026Article
- Comparative genomics of colistin-nonsusceptible multidrug-resistant Pseudomonas aeruginosa reveals emerging lineages in Thailand.Scientific reports · 2026Article
- Molecular Characterization of Cocarriage Carbapenemase Genes in ClinicalInternational journal of microbiology · 2026Article
- Antimicrobial resistance phenotypes, disinfectant susceptibility, and resistance-associated gene detection in carbapenem-resistant Pseudomonas aeruginosa from two tertiary hospitals in Urumqi, China.Frontiers in cellular and infection microbiology · 2026Article
- Coexistence of Multidrug Resistance and Hypervirulence-Associated Genes in Clinical Carbapenem-ResistantJournal of microbiology and biotechnology · 2025Article
- Antibiotics Resistance Profile of Clinical Isolates ofAntibiotics (Basel, Switzerland) · 2025Article
- Mechanical Ventilator-Associated Pneumonia in the COVID-19 Pandemic Era: A Critical Challenge in the Intensive Care Units.Antibiotics (Basel, Switzerland) · 2025Article
- High prevalence of carbapenem-resistantFrontiers in microbiology · 2025Article
- Impact of Sublethal Disinfectant Exposure on Antibiotic Resistance Patterns of Pseudomonasaeruginosa.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2025Article
- Occurrence of Plasmid-Mediated Quinolone Resistance and Carbapenemase-Encoding Genes inPathogens (Basel, Switzerland) · 2024Observational
- Critical resistance to carbapenem and aminoglycosides in Pseudomonas aeruginosa: spread of blaBMC infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.